Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Virology. 2018 Jul 26;522:244–259. doi: 10.1016/j.virol.2018.06.018

Fig. 7. Intracranial VSVΔG-CHIKV destroys brain glioma and enhances survival.

Fig. 7.

CB17 SCID mice with unilateral striatal xenografts of human rU87 glioma expressing RFP were treated with a single intracranial injection of either VSVΔG-CHIKV, VSV-LASV-GPC (2 μl of 3.0 ×108 PFU for each) or saline (control) 8 days after tumor implantation. VSVΔG-CHIKV-treated mice (n = 10) showed complete survival throughout the observation period (100 days) compared to untreated control (n = 10 each), and there was no obvious difference between VSVΔG-CHIKV-treated mice and VSV-LASV-GPC-treated mice.